Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artra GroupTSE:6029 -0.53%60 EV-to-EBIT is 15.92 as of Sep. 14, 2026, which is 140% above its 10-year median of 6.62. GuruFocus rates TSE:6029 with a GF Score™ of 60/100 and a GF Value™ of 円140.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 480 Healthcare Providers & Services companies, Artra Group ranks worse than 53.13% on this metric.
The historical rank and industry rank for Artra Group's EV-to-EBIT or its related term are showing as below:
TSE:6029'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1038.4 Med: 6.62 Max: 296.76
Current: 15.92
During the past 13 years, the highest EV-to-EBIT of Artra Group was 296.76. The lowest was -1038.40. And the median was 6.62.
TSE:6029's EV-to-EBIT is ranked worse than 53.13% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 15.06
vs TSE:6029: 15.92
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Artra Group's Enterprise Value for the quarter that ended in Jun. 2026 was 円1,480 Mil.
Artra Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artra Group EV-to-EBIT Related Terms
Artra Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Artra Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Artra Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artra Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artra Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Artra Group's EV-to-EBIT falls into.
Artra Group's current Enterprise Value is 円1,507 Mil.
Artra Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artra Group (TSE:6029) has a EV-to-EBIT of 15.92 as of Sep. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Artra Group and its competitors. This is 140% above median its historical median of 6.62. According to the industry distribution chart, Artra Group ranks #255 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 53.1%.
Is Artra Group's EV-to-EBIT too high?
Artra Group's current EV-to-EBIT of 15.92 is 140% above median its 10-year median of 6.62. The Healthcare Providers & Services industry median EV-to-EBIT is 15.06. Artra Group's value of 15.92 is 5.7% above this industry median. Based on the distribution chart, Artra Group ranks #255 out of 480 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Artra Group has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Artra Group's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Artra Group ranks #255 out of 480 companies for EV-to-EBIT. This places Artra Group in the lower half of its industry. The industry median EV-to-EBIT is 15.06. Artra Group's value of 15.92 is 5.7% above this benchmark. While the company's 10-year median is 6.62 vs. the industry median of 15.06, Artra Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.06, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artra Group's current EV-to-EBIT of 15.92 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Artra Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artra Group's current EV-to-EBIT is 15.92, which is 140% above median its own 10-year median of 6.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artra Group stock overvalued right now?
Based on GuruFocus' analysis, Artra Group (TSE:6029) is currently considered Significantly Overvalued. The stock's GF Value™ is 円140.54, compared to a current price of 円186.00 — trading 32.3% above its estimated fair value. The current EV-to-EBIT is 15.92, which is 140% above median its 10-year median of 6.62 and 5.7% above the Healthcare Providers & Services industry median of 15.06. Artra Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Artra Group (TSE:6029), the current EV-to-EBIT is 15.92 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artra Group (TSE:6029) Overvalued in 2026?
Based on GuruFocus' analysis, Artra Group stock appears to be overvalued.
The current stock price of 円186.00 is trading 32.3% above its estimated GF Value™ of 円140.54.
GuruFocus considers Artra Group to be Significantly Overvalued.
Key valuation signals for TSE:6029:
EV-to-EBIT: 15.92 (140% above median its 10-year median of 6.62)
GF Value™: 円140.54 vs. price of 円186.00 (32.3% above fair value)
Industry Position: 5.7% above the Healthcare Providers & Services median (#255 of 480)
No single metric tells the full story. See the TSE:6029 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artra Group Corp is engaged in the healthcare support business, providing services that assist the operation and management of clinics and related facilities. The group has two reportable segments: Acupuncture & Orthopedic Clinic Support and Toy Sales Business. The Acupuncture and Orthopedic Clinic Support segment is involved in supporting acupuncture and orthopedic clinics through services such as bone setting chains, provision of equipment and consumables, Attra billing services, HONEY-STYLE, and nursing care support. The Toy Sales segment focuses on the sale of toys, stationery, and other related products.
60GF Score
Get the complete analysis for TSE:6029
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6029 has been successfully added to your 
